Abstracts tagged "immunology"

Abstract Number: 2266 • ACR Convergence 2022
Platelet-selectin Prime Lupus Neutrophils to Produce Mitochondrial ROS and Participate in SLE Pathogenesis
Marc Scherlinger¹, Pierre Vacher², Vivien Guillotin³, Isabelle Douchet⁴, Christophe Richez⁵ and Patrick Blanco⁴, ¹BIDMC Harvard University, Boston, MA, ²INSERM U1218, Bordeaux, France, ³CHU de Bordeaux, Bordeaux, France, ⁴UMR-CNRS 5164 Immunoconcept, Bordeaux, France, ⁵CHRU Bordeaux, Bordeaux, France
Background/Purpose: In patients with active systemic lupus erythematosus (SLE), circulating platelets have an activated phenotype characterized by the expression of P-selectin (CD62P). We have shown…
Abstract Number: 0506 • ACR Convergence 2022
Immunophenotypic Categorization of Systemic Immune-mediated Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura² and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Japan, ⁴Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, the Institute of Physical and Chemical Research (RIKEN), Wako, Saitama, Japan
Background/Purpose: Systemic immune-mediated diseases are heterogeneous, and the pathogenesis varies among and within each disease. Some studies tried to stratify patients with immune-mediated diseases into…
Abstract Number: 0662 • ACR Convergence 2022
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The immunopathogenesis of cutaneous lupus erythematous (CLE) is highly diverse and involves activity of many different cell types and pathways. This heterogeneity is believed…
Abstract Number: 0994 • ACR Convergence 2022
Effect of Immunosuppression on COVID Vaccination in Systemic Lupus Erythematosus
Michelle Petri¹, Daniel Joyce², Kristin Haag², Andrea Fava³, Daniel W. Goldman¹, Diana Zhong², Shaoming Xiao⁴, Aaron M. Milstone² and Laurence S Magder⁵, ¹Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵University of Maryland, Department of Epidemiology and Public Health, Baltimore, MD
Background/Purpose: The risk of COVID-19 infection is increased in patients with systemic lupus erythematosus (SLE), and immunosuppressive medications including corticosteroids impact the risk. Furthermore, immunosuppressive…
Abstract Number: 1683 • ACR Convergence 2022
Malondialdehyde-Acetaldehyde (MAA) Modified Matrix Gla Protein (MGP) Increases Citrullination by Human Macrophages
Spencer Jones¹, nozima Aripova¹, Michael Duryee¹, Austin Ragland¹, Bryant England¹, Ted Mikuls² and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Malondialdehyde and acetaldehyde, by-products of lipid peroxidation, react with free amino groups on proteins to form a stable post-translational modification (PTM), termed MAA. MAA…
Abstract Number: 1747 • ACR Convergence 2022
Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis
Cliff Rims¹, Virginia Muir¹, Anne Hocking¹, Sylvia Posso¹, Heather Bukiri², Jeffrey Carlin³, Bernard Ng⁴, Peter Linsley¹, Eddie James⁵ and Jane Buckner⁵, ¹Benaroya Research Institute, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Virginia Mason Medical Center, Seattle, WA, ⁴VA Puget Sound HCS, Seattle, WA, ⁵Benaroya Research Institute at Virginia Mason, Seattle, WA
Background/Purpose: In Rheumatoid arthritis (RA) citrullinated antigen reactive T cells are key drivers of disease, but knowledge about their relative number and phenotype remains limited.…
Abstract Number: 2267 • ACR Convergence 2022
Plasmacytoid Dendritic Cells Are Not Major Producers of Type 1 Interferons in Cutaneous Lupus
Thomas Vazquez¹, Nilesh Kodali¹, DeAnna Diaz², Jay Patel³, Emily Keyes², Grant Sprow², Meena Sharma¹, Mariko Ogawa-Momohara², Madison Grinnell², Josh Dan² and Victoria Werth², ¹Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN
Background/Purpose: Type 1 interferons (IFN-1) are major drivers of disease activity in systemic (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs) are the…
Abstract Number: 0511 • ACR Convergence 2022
SARS-CoV-2 mRNA Vaccine Immunogenicity in Chronic Inflammatory Arthritis on DMARD Therapy
Nedal Darwish¹, Sameer Jhaveri², Uma Yoganathan¹, Halima Bakillah¹, Kelly Y. Chun³, Thomas Wasser⁴ and James Freeman¹, ¹Arnot Ogden Medical Center, Elmira, NY, ²Lake Erie College of Osteopathic Medicine, Elmira, NY, ³Labcorp, Calabasas, CA, ⁴Consult-Stat, Macungie, PA
Background/Purpose: Patients with chronic inflammatory arthritis (CIA) are at increased risk for the development and mortality from COVID-19. Vaccinations are integral to the management of…
Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…
Abstract Number: 1059 • ACR Convergence 2022
Vision Transformer Assisting Rheumatologists in Screening for Capillaroscopy Changes in Systemic Sclerosis: An Artificial Intelligence Solution
Alexandru Garaiman¹, Farhad Nooralahzadeh², Carina Mihai¹, Nikitas Gkikopoulos¹, Nicolas Perez Gonzalez², Mike Becker¹, Oliver Distler¹, Michael Krauthammer³ and Britta Maurer⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ²Department of Biomedical Informatics, University of Zurich, Zürich, Switzerland, ³Department of Quantitative Biomedicine, University of Zurich, Zürich, Switzerland, ⁴Department of Rheumatology and Immunology, University Hospital Bern, University of Bern, Bern, Switzerland
Background/Purpose: An accurate assessment of nailfold capillaroscopy (NFC) images has great importance in the diagnosis and prognosis of systemic sclerosis (SSc). To overcome some of…
Abstract Number: 1687 • ACR Convergence 2022
A Core Inflammation Program Conserved Across Human and Murine Neutrophils
Nicolaj hackert¹, Felix Radtke¹, Tarik Exner¹, Carsten Müller-Tidow¹, Hanns-Martin Lorenz¹, Peter Nigrovic², Guido Wabnitz¹ and Ricardo Grieshaber-Bouyer¹, ¹Heidelberg University Hospital, Heidelberg, Germany, ²Boston Children's Hospital, Boston, MA
Background/Purpose: Neutrophils mediate a range of homeostatic and inflammatory processes and display substantial phenotypic and functional heterogeneity. While animal models enable important mechanistic discoveries, differences…
Abstract Number: 1749 • ACR Convergence 2022
Mass Spectrometry-Based HLA Peptidomics Analysis Reveals Both Expected and Novel Citrullinated Antigen Targets in Rheumatoid Arthritis
Eddie James¹, Cliff Rims², Sylvia Posso², Jeffrey Carlin³, William Kwok², Shao-En Ong⁴ and Jane Buckner¹, ¹Benaroya Research Institute at Virginia Mason, Seattle, WA, ²Benaroya Research Institute, Seattle, WA, ³Virginia Mason Medical Center, Seattle, WA, ⁴University of Washington, Seattle, WA
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease in which citrullinated self-antigens are recognized by anti-citrullinated protein antibodies (ACPA) and T cells. ACPA are a…
Abstract Number: L20 • ACR Convergence 2021
Efficacy of Emapalumab, an Anti-IFNγ Antibody in Patients with Macrophage Activation Syndrome (MAS) Complicating Systemic Juvenile Idiopathic Arthritis (sJIA) Who Had Failed High-Dose Glucocorticoids (GCs)
Fabrizio De Benedetti¹, Alexei Grom², Paul Brogan³, Claudia Bracaglia¹, Manuela Pardeo¹, Giulia Marucci¹, Despina Eleftheriou³, Charalampia Papadopoulou³, Pierre Quartier⁴, Jordi Antón⁵, Rikke Frederiksen⁶, Veronica Asnaghi⁶ and Cristina De Min⁶, ¹Bambino Gesù Children's Hospital IRCCS, Rome, Italy, ²Cincinnati Children’s Hospital, Division of Rheumatology, Cincinnati, OH, ³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁴Université de Paris, IMAGINE Institute, RAISE reference centre, Pediatric Immuno-Hematology and Rheumatology Unit, Necker Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁵Hospital Sant Joan de Déu, Division of Pediatric Rheumatology, University of Barcelona, Barcelona, Spain, ⁶Swedish Orphan Biovitrum AG (Sobi), Basel, Switzerland
Background/Purpose: MAS is a life-threatening complication of rheumatic diseases, occurring most frequently in sJIA. The mainstay of MAS treatment is high dose GCs; however, GCs…
Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Ines Colmegna¹, Mariana Useche¹, Emmanouil Rampakakis², Nathalie Amiable³, Emmanuelle Rollet-Labelle³, Louis Bessette⁴, Jo-Anne Costa⁴, Marc Dionne⁴, Mary-Ann Fitzcharles², Elizabeth Hazel², Deirdre McCormack², Laetitia Michou⁴, Pantelis Panopalis², Marc-Andre Langlois⁵, Sasha Bernatsky⁶ and Paul R. Fortin⁷, ¹The Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University Health Centre, Montreal, QC, Canada, ³Centre de Recherche du CHU de Quebec, Quebec, Canada, ⁴Universite Laval, Quebec, QC, Canada, ⁵University of Ottawa, Ottawa, ON, Canada, ⁶McGill University, Montreal, QC, Canada, ⁷CHU de Quebec - Universite Laval, Quebec, Canada
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…
Abstract Number: 0262 • ACR Convergence 2021
High Degree of Inter-patient Heterogeneity in Synoviocyte Hyperplasia and Immune Cells Infiltration in the Synovium of Juvenile Idiopathic Arthritis Patients
Clément TRIAILLE¹, Cécile BOULANGER², Tatiana SOKOLOVA¹, Laurent MERIC de BELLEFON³, Adrien NZEUSSEU TOUKAP⁴, Christine GALANT⁵, Nisha LIMAYE⁶, Bernard LAUWERYS⁷ and Patrick DUREZ⁸, ¹Pôle de pathologies rhumatismales systémiques et inflammatoires, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ²Service d’Hématologie, Oncologie et Rhumatologie pédiatrique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Rheumatology department, Cliniques Universitaires Saint-Luc, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain, Brussels, Belgium, ⁵Service d’Anatomie Pathologique, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁶Genetics of Autoimmune Diseases and Cancer, de Duve Institute, Université catholique de Louvain, Brussels, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸Pôle de Recherche en Rhumatologie, Institut de Recherche Expérimentale et Clinique, Brussels, Belgium
Background/Purpose: Increasing evidence indicates that synovial tissue analysis can deliver pathophysiological insights but also individual clinically-relevant information in adult-onset inflammatory arthritides. Little is known about…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.